Hester Biosciences shares surged over 8% in early trade on Thursday, November 5, after the veterinary healthcare maker turned in an explosive operational second quarter. Buyers swept into the counter at the opening bell. Net profit for the September quarter jumped 41% year-on-year to ₹20.3 crore, compared with ₹14.4 crore in the identical period last year, according to regulatory filings.
Topline momentum matched the bottom-line strength. Revenue rose 38% to ₹98 crore from ₹71 crore twelve months earlier, driven by broad-based volume uptake. Operating leverage, however, delivered the real shock to market models. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) more than doubled, landing at ₹33 crore against ₹11.5 crore a year ago. That hoisted operating margin to 33.4%—a massive expansion from the 16.2% logged in the prior-year quarter.
| Metric | Q2 Current Year | Q2 Previous Year | YoY Change |
|---|---|---|---|
| Revenue | ₹98 crore | ₹71 crore | +38% |
| Net Profit | ₹20.3 crore | ₹14.4 crore | +41% |
| EBITDA | ₹33 crore | ₹11.5 crore | +187% |
| EBITDA Margin | 33.4% | 16.2% | +1,720 bps |
Beyond the core ledger, management moved to shore up its international manufacturing footprint. The company's board approved an unsecured loan of $1 million to Hester Biosciences Africa Ltd., its wholly owned subsidiary based in Tanzania. The credit line will disburse in one or more tranches to finance ongoing business operations, general corporate purposes, and immediate working capital requirements.
Because Hester holds an absolute 100% equity stake in the African manufacturing operation, the transaction qualifies under related-party provisions governed by the SEBI Listing Regulations. The unit remains central to the firm's continental vaccination outreach.
With operating profitability doubling and offshore liquidity locked in, institutional eyes now turn to whether the company can sustain its 33% margin threshold into the second half of the fiscal year.